SCHEMBL14716600

SCHEMBL14716600

CCc1ccc(N=Nc2nc3c(=O)[nH]c(NC(C)=O)nc3[nH]2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
GDA Q9Y2T3 1/20 0.38
FGFR1 P11362 4/20 0.37
FGFR2 P21802 4/20 0.37
MAPT P10636 3/20 0.37
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
POLB P06746 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
BLM P54132 1/20 0.37
ALOX15 P16050 1/20 0.37
PKM P14618 1/20 0.37
KLF5 Q13887 1/20 0.37
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
TSHR P16473 1/20 0.36
LMNA P02545 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14729789 1.00 ALDH1A1 (0.41) ALDH1A1KDM4EGAAGDAFGFR1
SCHEMBL12320829 0.87 TDP1 (0.49) ALDH1A1KDM4EGAAGDAFGFR1
SCHEMBL14716736 0.84 TDP1 (0.44) KDM4EGAAGDAFGFR1FGFR2
SCHEMBL14729742 0.84 TDP1 (0.44) KDM4EGAAGDAFGFR1FGFR2
SCHEMBL14716598 0.83 FGFR1 (0.51) ALDH1A1KDM4EGAAGDAFGFR1
SCHEMBL14716709 0.80 TYMS (0.41) ALDH1A1KDM4EMAPTPOLBALOX15
SCHEMBL12321218 0.80 TYMS (0.41) ALDH1A1KDM4EMAPTPOLBALOX15
SCHEMBL14729780 0.77 MAPT (0.40) ALDH1A1KDM4EGAAGDAFGFR1
SCHEMBL14716707 0.74 TDP1 (0.46) ALDH1A1KDM4EGAAGDAFGFR1
SCHEMBL23771217 0.70 RAB9A (0.67) ALDH1A1MAPTNPC1RAB9ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458515-B2 RNA including nucleoside compound, method for regulating amount of protein produced from the RNA, and nucleoside compound RIKEN (JP) 2016-10-04 US disclosed
US-20130052710-A1 RNA INCLUDING NUCLEOSIDE COMPOUND, METHOD FOR REGULATING AMOUNT OF PROTEIN PRODUCED FROM THE RNA, AND NUCLEOSIDE COMPOUND RIKEN (JP) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130052710-A1 RNA INCLUDING NUCLEOSIDE COMPOUND, METHOD FOR REGULATING AMOUNT OF PROTEIN PRODUCED FROM THE RNA, AND NUCLEOSIDE COMPOUND RNMT, NSUN2, RNGTT ALDH1A1 4385/4885KDM4E 1577/4885GAA 3753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.